Get informed when a big investor buys or sells
+ Follow-133.71%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Caribou Biosciences (CRBU) currently reports a ROE of -133.71%. That is below the Healthcare sector average of 13.1%. Use the charts on this page to explore Caribou Biosciences's ROE history and peer comparisons.
Caribou Biosciences's ROE of -133.71% is lower than the Healthcare sector average of 13.1%. That is roughly 1120.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Caribou Biosciences's current -133.71% should be judged against Healthcare norms (sector average: 13.1%) and against CRBU's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -133.71%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.1%. From there, open related valuation or income-statement pages for Caribou Biosciences, and consider following CRBU for alerts when major investors trade the stock.
Caribou Biosciences is classified in the Healthcare sector. On ROE, it currently shows -133.71% versus a sector average near 13.1%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CRBU with unrelated industries.